博拓生物(688767) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 reached ¥1,017,267,845.08, representing a year-on-year increase of 106.83%[5] - Net profit attributable to shareholders was ¥492,528,719.71, reflecting a growth of 111.25% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥484,445,824.96, an increase of 107.92% year-on-year[10] - Basic earnings per share were ¥4.62, up by 58.68% from the previous year[10] - Operating profit for Q1 2022 was ¥582,914,745.56, up 113.0% from ¥273,429,534.36 in the same period last year[23] - Net profit for Q1 2022 was ¥493,587,345.24, representing a 112.5% increase from ¥232,739,290.16 in Q1 2021[23] - Total operating costs for Q1 2022 were ¥445,116,101.97, which is 106.7% higher than ¥215,002,694.83 in Q1 2021[22] - The total comprehensive income for Q1 2022 was ¥493,573,794.84, up from ¥232,646,007.62 in Q1 2021[24] Cash Flow and Assets - The net cash flow from operating activities was ¥696,516,794.88, showing a significant increase of 131.89%[10] - Cash flow from operating activities for Q1 2022 was ¥696,516,794.88, an increase of 132.9% from ¥300,369,138.70 in Q1 2021[26] - Cash and cash equivalents at the end of Q1 2022 totaled ¥2,017,795,409.79, up from ¥523,392,039.85 at the end of Q1 2021[26] - The company's cash and cash equivalents reached ¥2,017,919,909.79, up from ¥1,367,736,419.05, indicating a growth of about 47.5%[18] - Total assets at the end of the reporting period amounted to ¥3,181,979,046.82, a 30.86% increase from the end of the previous year[6] - As of March 31, 2022, the total assets of the company amounted to ¥3,181,979,046.82, an increase from ¥2,431,508,922.58 at the end of December 2021, representing a growth of approximately 31%[19] - The company reported a total current assets of ¥2,756,825,709.92, up from ¥2,032,709,544.64, which is an increase of approximately 35.5%[19] Liabilities and Equity - Total current liabilities increased to ¥575,044,013.77 from ¥317,560,242.74, reflecting a rise of approximately 81%[20] - The company’s total liabilities reached ¥580,255,822.87, up from ¥323,359,493.47, indicating an increase of about 79.5%[20] - The company's total equity attributable to shareholders rose to ¥2,599,614,662.82, compared to ¥2,107,098,138.47, marking an increase of around 23.3%[20] - The company’s retained earnings increased to ¥1,623,986,917.39 from ¥1,131,458,197.68, reflecting a growth of approximately 43.4%[20] Research and Development - Research and development expenses totaled ¥19,586,991.87, which is 60.31% higher than the same period last year[10] - Research and development expenses for Q1 2022 amounted to ¥19,586,991.87, an increase of 60.5% from ¥12,218,054.31 in Q1 2021[22] - The proportion of R&D expenses to operating revenue was 1.93%, a decrease of 0.55 percentage points[6] Accounting and Reporting - The company announced the implementation of new accounting standards starting from Q1 2022[27] - The financial statements related to the first execution of the new accounting standards were adjusted at the beginning of the year[27] - The board of directors of Hangzhou Botao Biotechnology Co., Ltd. issued the report on April 26, 2022[27] - The report indicates that it is not applicable to the new accounting standards for the first quarter of 2022[27] - The document does not provide specific financial performance metrics or user data for Q1 2022[27] - There are no future outlooks or performance guidance mentioned in the report[27] - The report lacks information on new product or technology development[27] - There are no details regarding market expansion or mergers and acquisitions[27] - The document does not outline any new strategies[27] - The report consists of 15 pages, indicating a comprehensive overview of the company's financial status[27]